United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond Sells 12,000 Shares

United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) CFO James Edgemond sold 12,000 shares of United Therapeutics stock in a transaction on Monday, June 9th. The shares were sold at an average price of $325.37, for a total value of $3,904,440.00. Following the completion of the sale, the chief financial officer now directly owns 8,118 shares of the company's stock, valued at approximately $2,641,353.66. This represents a 59.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR traded up $8.61 during midday trading on Thursday, hitting $285.08. 595,299 shares of the company's stock traded hands, compared to its average volume of 450,839. The firm's fifty day moving average price is $300.54 and its two-hundred day moving average price is $332.08. United Therapeutics Co. has a twelve month low of $266.98 and a twelve month high of $417.82. The company has a market cap of $12.86 billion, a PE ratio of 12.52, a P/E/G ratio of 0.97 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. During the same quarter in the previous year, the firm posted $6.17 earnings per share. The firm's quarterly revenue was up 17.2% on a year-over-year basis. As a group, equities research analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of UTHR. Bleakley Financial Group LLC grew its position in United Therapeutics by 58.1% in the fourth quarter. Bleakley Financial Group LLC now owns 1,059 shares of the biotechnology company's stock valued at $374,000 after acquiring an additional 389 shares in the last quarter. Newbridge Financial Services Group Inc. purchased a new position in shares of United Therapeutics in the fourth quarter valued at $25,000. Savant Capital LLC grew its holdings in United Therapeutics by 2.7% during the 4th quarter. Savant Capital LLC now owns 10,205 shares of the biotechnology company's stock valued at $3,601,000 after purchasing an additional 266 shares in the last quarter. JSF Financial LLC grew its holdings in United Therapeutics by 4.0% during the 4th quarter. JSF Financial LLC now owns 2,996 shares of the biotechnology company's stock valued at $1,057,000 after purchasing an additional 114 shares in the last quarter. Finally, Louisiana State Employees Retirement System increased its stake in United Therapeutics by 0.8% during the 4th quarter. Louisiana State Employees Retirement System now owns 12,400 shares of the biotechnology company's stock worth $4,375,000 after buying an additional 100 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several recent analyst reports. Bank of America cut their price objective on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a report on Wednesday. HC Wainwright reaffirmed a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a research report on Monday, May 5th. Wall Street Zen lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. JPMorgan Chase & Co. lowered their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st. Finally, Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $314.00 target price (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, United Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $393.08.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.